An observational study in Alopecia Areata and Janus Kinase Inhibitors, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Recruiting at 1 site in China. Open to participants aged 2 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-08-27.
Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Alopecia Areata with a site in China — 9 open to participants now, 13 under way, 6 of them phase 3. Alopecia Areata · China.
Among the 24 studies in Alopecia Areata with a site in China, this one is one of 3 that started in 2024, is one of 2 observational ones, reaches primary completion later than 2 of the 12 other live ones, and was the 16th registered.
222 studies on the registry are indexed under Alopecia Areata; 63 are open to participants now.
Browse Alopecia Areata studies →9 of the 24 studies in Alopecia Areata with a site in China are open now. Recruiting first, the newest first:
Jiangsu vcare pharmaceutical technology co., LTD · Sites in China
Ages 12–18
Jiangsu vcare pharmaceutical technology co., LTD · Sites in China
Ages 18–65
Pfizer · Sites in China, United States, Canada and 2 more countries
Ages 12+
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 18–80 · Healthy volunteers
Eli Lilly and Company · Sites in China, United States, Canada and 4 more countries
Ages 18–60
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 43 Alopecia Areata studies recruiting now, 17 (40%) set no upper age limit and 22 (51%) stop at 75 or younger; 20 take children under 18; 6 take healthy volunteers.
This study: 2 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 9 · Phase 3 11
First in 2012; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is below the median of 384 across 40 observational studies indexed under Alopecia Areata.
Median enrollment 163 across the 22 interventional studies, 300 across the 2 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 24 have an industry lead sponsor. The 10 most frequent:
Second Affiliated Hospital, School of Medicine, Zhejiang University is the lead sponsor of 1,042 studies on the registry; 499 are open to participants now.
Second Affiliated Hospital, School of Medicine, Zhejiang University has 2 studies filed under Alopecia Areata — fewer than ten, so there is no comparison to draw.
3 of the studies in Alopecia Areata with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07029711Phase 3PfizerA Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata | 2026-12-02 |
| NCT06573593Second Affiliated Hospital, School of Medicine, Zhejiang UniversityEfficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study | 2026-12-31 |
| NCT07533006Eli Lilly and CompanyA Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies in Alopecia Areata with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The introduction of Janus Kinase inhibitors (JAKi) seems to revolutionize the field of alopecia areata (AA) therapeutics. However, the ideal JAKi is not yet settled and the real-world data are still missing. To provide evidence about effectiveness and safety of different JAKi including tofacitinib, baricitinib, ritlecitinib,abrocitinib, upadacitinib and ifidancitinib in real-world settings and describe baseline disease characteristics and patients profiles that are considered good candidates for JAKi in the daily practice. Furthermore, we intended to investigate the efficacy and safety of JAK Inhibitors in patients With AA, as well as to provide clinical evidence for the clinicians and patients when they formulate individualized treatment plans.
Patients diagnosed with alopecia areata treated with JAKi including tofacitinib, baricitinib, ritlecitinib,abrocitinib, upadacitinib and ifidancitinib for more than 3 months in Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
In the real-world settings, patients with AA treated with tofacitinib.
Drug: Tofacitinib
In the real-world settings, patients with AA treated with baritinib.
Drug: Baricitinib
In the real-world settings, patients with AA treated with ruxolitinib
Drug: Ruxolitinib
In the real-world settings, patients with AA treated with upadacitinib.
Drug: Upadacitinib
In the real-world settings, patients with AA treated with abhicitinib.
Drug: Abrocitinib
In the real-world settings, patients with AA treated with ritlecitinib.
Drug: Ritlecitinib
In the real-world settings, patients with AA treated with tofacitinib.
In the real-world settings, patients with AA treated with Baricitinib.
In the real-world settings, patients with AA treated with Ruxolitinib.
In the real-world settings, patients with AA treated with Upadacitinib.
In the real-world settings, patients with AA treated with Abrocitinib.
In the real-world settings, patients with AA treated with Ritlecitinib.
Mean SALT
Reduction of Severity of Alopecia Tool (SALT) score compared with baseline
Time frame: at week 24
SALT50
Percentage of patient with more than 50% improvement in SALT score
Time frame: at week 24
SALT75
Percentage of patient with more than 70% improvement in SALT score
Time frame: at week 24
Mean SALT
Reduction of Severity of Alopecia Tool (SALT) score compared with baseline
Time frame: at week 12, 36, 48, 56
SALT50
Percentage of patient with more than 75% improvement in SALT score
Time frame: at week 12, 36, 48, 56
SALT75
Percentage of patient with more than 50% improvement in SALT score
Time frame: at week 12, 36, 48, 56
Safety profile
Any adverse events including infection, hypohepatia, thrombus, gastrointestinal reaction and any other system events.
Time frame: at week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 29 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Second Affiliated Hospital, School of Medicine, Zhejiang University →